title: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate the short- and long-term safety of infliximab in patients with Crohn's disease in clinical practice.
  
  
  METHODS
  The medical records of 500 consecutive patients treated with infliximab at the Mayo Clinic were reviewed and abstracted for demographic features and adverse events. The likelihood of a causal relationship to infliximab for each adverse event was determined by calculating an intrinsic likelihood (imputability) score.
  
  
  RESULTS
  The 500 patients received a median of 3 infusions and had a median follow-up of 17 months. Forty-three patients (8.6%) experienced a serious adverse event, of which 30 (6%) were related to infliximab. Acute infusion reactions occurred in 19 of 500 patients (3.8%). Serum sickness-like disease occurred in 19 of 500 patients and was attributed to infliximab in 14 (2.8%). Three patients developed drug-induced lupus. One patient developed a new demyelination disorder. Forty-eight patients had an infectious event, of which 41 (8.2%) were attributed to infliximab. Twenty patients had a serious infection: 2 had fatal sepsis, 8 had pneumonia (of which 2 cases were fatal), 6 had viral infections, 2 had abdominal abscesses requiring surgery, one had arm cellulitis, and one had histoplasmosis. Nine patients had a malignant disorder, 3 of which were possibly related to infliximab. A total of 10 deaths were observed. For 5 of these patients (1%), the events leading to death were possibly related to infliximab.
  
  
  CONCLUSIONS
  Short- and long-term infliximab therapy is generally well tolerated. However, clinicians must be vigilant for the occurrence of infrequent but serious events, including serum sickness-like reaction, opportunistic infection and sepsis, and autoimmune disorders.
authors.affiliation: Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Jean-Frederic
authors.initials: JF
authors.lastname: Colombel
authors.forename: Edward V
authors.initials: EV
authors.lastname: Loftus
authors.forename: William J
authors.initials: WJ
authors.lastname: Tremaine
authors.forename: Laurence J
authors.initials: LJ
authors.lastname: Egan
authors.forename: W Scott
authors.initials: WS
authors.lastname: Harmsen
authors.forename: Cathy D
authors.initials: CD
authors.lastname: Schleck
authors.forename: Alan R
authors.initials: AR
authors.lastname: Zinsmeister
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D003424:Crohn Disease / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007239:Infections / Q000139:chemically induced / Q000401:mortality; D000069285:Infliximab; D016013:Likelihood Functions; D008177:Lupus Vulgaris / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced; D012189:Retrospective Studies; D012713:Serum Sickness / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab